Capecitabine

Drug Profile

Capecitabine

Alternative Names: Capecitabine RDT; R340; RG 340; RO 091978; Ro09-1978; Xeloda; Xelox

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Roche; Samsung Medical Center; Sanofi; University of Chicago
  • Class Antineoplastics; Carbamates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer
  • Registered Rectal cancer
  • Phase II Glioma; Oesophageal cancer; Pancreatic cancer
  • No development reported Cervical cancer; Lung cancer; Nasopharyngeal cancer
  • Discontinued Biliary cancer

Most Recent Events

  • 01 Apr 2017 Roche terminates a phase III trial in Colorectal cancer (First-line therapy, Metastatic disease) in South Korea (PO) (NCT02060669)
  • 10 Jan 2017 Roche completes a phase III trial in Breast cancer (Combination therapy, Early-stage disease) in Portugal, Italy, United Kingdom, Germany, Slovenia, Spain, Belgium, Netherlands (PO) (NCT00433589)
  • 26 Aug 2016 Registered for Rectal cancer (Adjuvant therapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top